Clinical Trial Update: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and activity of combining a MEK inhibitor with an AKT inhibitor in patients with multiple myeloma or solid tumors has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• AKT inhibitor (AKT inhibitor)
• MEK inhibitor

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED